CAMP4 Therapeutics (NASDAQ:CAMP) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of CAMP4 Therapeutics (NASDAQ:CAMP) from a sell rating to a hold rating in a research note published on Saturday,Wall Street Zen reports.

Other equities research analysts have also issued research reports about the company. Raymond James Financial began coverage on CAMP4 Therapeutics in a research note on Friday, October 23rd. They issued a “strong-buy” rating and a $10.00 target price on the stock. Weiss Ratings raised CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 16th. Needham & Company LLC assumed coverage on CAMP4 Therapeutics in a research report on Thursday, October 15th. They set a “buy” rating and a $8.00 price target for the company. UBS Group set a $15.00 price target on CAMP4 Therapeutics in a report on Friday, August 14th. Finally, Piper Sandler restated an “overweight” rating and issued a $15.00 price objective (up from $12.00) on shares of CAMP4 Therapeutics in a research report on Friday, August 14th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $10.44.

CAMP4 Therapeutics Trading Up 15.5%

Shares of CAMP opened at $4.69 on Friday. The stock has a market cap of $294.30 million, a P/E ratio of -2.19 and a beta of 0.28. The company has a 50-day moving average of $3.85 and a two-hundred day moving average of $4.20. CAMP4 Therapeutics has a 12-month low of $2.90 and a 12-month high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP) last announced its quarterly earnings results on Thursday, November 5th. The Wireless communications provider reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.17). The business had revenue of $1.90 million during the quarter. CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative return on equity of 252.79%. As a group, analysts forecast that CAMP4 Therapeutics will post -0.68 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Kelly Gold acquired 10,000 shares of CAMP4 Therapeutics stock in a transaction that occurred on Monday, August 31st. The shares were acquired at an average price of $3.96 per share, with a total value of $39,600.00. Following the completion of the purchase, the chief financial officer owned 10,000 shares of the company’s stock, valued at approximately $39,600. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Andrew Schwab sold 400,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $4.04, for a total transaction of $1,616,000.00. Following the sale, the director owned 2,033,270 shares in the company, valued at approximately $8,214,410.80. This trade represents a 16.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 593,613 shares of company stock valued at $2,504,037. Company insiders own 21.69% of the company’s stock.

Hedge Funds Weigh In On CAMP4 Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Jupiter Topco LLC purchased a new position in CAMP4 Therapeutics during the second quarter worth approximately $27,581,000. 5AM Venture Management LLC purchased a new position in CAMP4 Therapeutics in the 2nd quarter worth approximately $25,647,928. Trails Edge Capital Partners LP purchased a new position in CAMP4 Therapeutics in the 2nd quarter worth approximately $8,446,935. BlackRock Inc. acquired a new stake in CAMP4 Therapeutics in the second quarter valued at approximately $7,185,000. Finally, SummitTX Capital L.P. acquired a new stake in CAMP4 Therapeutics in the first quarter valued at approximately $1,497,000.

About CAMP4 Therapeutics

CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing medicines that increase the production of disease-relevant proteins by activating the expression of specific genes. The company’s approach is designed to address diseases caused by insufficient protein levels, including certain genetic disorders in which boosting activity from a functional gene copy may provide therapeutic benefit.

CAMP4 uses its Regulatory Action Platform, or RAP, to identify regulatory elements that control RNA production and discover small-molecule compounds capable of increasing the expression of selected genes.